Market revenue in 2023 | USD 364.3 million |
Market revenue in 2030 | USD 509.1 million |
Growth rate | 4.9% (CAGR from 2023 to 2030) |
Largest segment | Consulting |
Fastest growing segment | Training & Education |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Consulting, Regulatory Affairs, Product Design & Development, Auditing and Assessment, Product Maintenance, Training & Education |
Key market players worldwide | PAREXEL, IQVIA Holdings Inc, Heidelberg Materials AG, Labcorp Holdings Inc, Charles River Laboratories International Inc, Icon PLC, Syneos Health, Lonza Group Ltd, Catalent Inc, Samsung BioLogics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biotechnology and pharmaceutical services outsourcing market will help companies and investors design strategic landscapes.
Consulting was the largest segment with a revenue share of 50.65% in 2023. Horizon Databook has segmented the Sweden biotechnology and pharmaceutical services outsourcing market based on consulting, regulatory affairs, product design & development, auditing and assessment, product maintenance, training & education covering the revenue growth of each sub-segment from 2018 to 2030.
The biotechnology & pharmaceutical services outsourcing market in Sweden is highly competitive, with domestic and international manufacturers operating in the country. The market is driven by rising innovation, with the increasing number of clinical trials in Sweden.
The country has a strong R&D infrastructure, with several universities and research institutes collaborating with the biotechnology & pharmaceutical industry to drive innovation & develop new therapies.
Furthermore, Sweden’s increasing demand for biotechnology & pharmaceutical outsourcing services (CROs, CMOs, & CDMOs) can be attributed to the growing approvals granted by the Swedish government for advanced manufacturing lines.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden biotechnology and pharmaceutical services outsourcing market , including forecasts for subscribers. This country databook contains high-level insights into Sweden biotechnology and pharmaceutical services outsourcing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account